Opko Health, Inc. - Common Stock (OPK)

OPKO Health (NASDAQ:OPK) reported a narrower second-quarter loss as gains tied to its diagnostics restructuring and a China commercialization agreement helped lift revenue, while the company continued to increase investment in clinical development programs. Total revenue for the second quarter of 2

OPKO Health (OPK) Q4 2025 Earnings Call Transcript

OPKO Health Q3 2025 earnings beat estimates with a surprise profit, driving a positive market reaction despite a revenue miss.

OPKO Health's Q2 2025 earnings missed revenue and EPS estimates, causing a 7.8% stock drop. Weak performance in pharma/diagnostics segments and higher losses raised investor concerns.

Late Friday, the company said the U.S.-China tariffs will have a material impact on anticipated sales of U.S. products into China.

OPK earnings call for the period ending December 31, 2024.

Insider trades are a telling indicator of C-Suite conviction but aren't always the signal for investors they could be. Only two of these stocks are good buys.

OPK earnings call for the period ending September 30, 2024.

OPK earnings call for the period ending June 30, 2024.